Similarly, studies on FGF21 in patients with type II endometrium and slim patients in older age seem to confirm that FGF acts as an independent factor in endometrial cancer, via FGFR 2 and the PI3K/Akt, mTOR signaling pathways. Here, MTOR is linked to endometrial cancer.